Gene description for SZT2 |
Gene name |
seizure threshold 2 homolog (mouse) |
Gene symbol |
SZT2 |
Other names/aliases |
C1orf84 EIEE18 KIAA0467 SZT2A SZT2B |
Species |
Homo sapiens |
Database cross references - SZT2 |
ExoCarta |
ExoCarta_23334 |
Entrez Gene |
23334 |
HGNC |
29040 |
MIM |
615463 |
UniProt |
Q5T011
|
SZT2 identified in exosomes derived from the following tissue/cell type |
Mesenchymal stem cells
|
Unpublished / Not applicable
|
Neuroblastoma cells
|
25944692
|
Prostate cancer cells
|
25844599
|
Gene ontology annotations for SZT2 |
|
Experiment description of studies that identified SZT2 in exosomes |
1 |
Experiment ID |
126 |
ISEV standards |
✘
|
EV Biophysical techniques |
✔
GAPDH
|
EV Cytosolic markers |
✘
|
EV Membrane markers |
✘
|
EV Negative markers |
✘
|
EV Particle analysis
|
|
Identified molecule |
protein
|
Identification method |
Mass spectrometry [LTQ-FT Ultra]
|
PubMed ID |
Unpublished / Not applicable
|
Organism |
Homo sapiens |
Experiment description |
Mesenchymal Stem Cell Exosomes: The Future MSC-based Therapy? |
Authors |
Ruenn Chai Lai, Ronne Wee Yeh Yeo, Soon Sim Tan, Bin Zhang, Yijun Yin, Newman Siu Kwan Sze, Andre Choo, and Sai Kiang Lim |
Journal name |
Mesenchymal Stem Cell Therapy
|
Publication year |
2011 |
Sample |
Mesenchymal stem cells |
Sample name |
huES9.E1 |
Isolation/purification methods |
HPLC |
Flotation density |
-
|
Molecules identified in the study |
Protein |
Methods used in the study |
Western blotting Antobody array Mass spectrometry |
|
|
2 |
Experiment ID |
224 |
ISEV standards |
✔
EM|AFM
|
EV Biophysical techniques |
✔
Alix|TSG101
|
EV Cytosolic markers |
✔
CD63|CD81
|
EV Membrane markers |
✔
GOLGA2
|
EV Negative markers |
✘
|
EV Particle analysis
|
|
Identified molecule |
protein
|
Identification method |
Mass spectrometry
|
PubMed ID |
25944692
|
Organism |
Homo sapiens |
Experiment description |
Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes |
Authors |
Keerthikumar S, Gangoda L, Liem M, Fonseka P, Atukorala I, Ozcitti C, Mechler A, Adda CG, Ang CS, Mathivanan S |
Journal name |
Oncotarget
|
Publication year |
2015 |
Sample |
Neuroblastoma cells |
Sample name |
SH-SY5Y |
Isolation/purification methods |
Differential centrifugation Ultracentrifugation OptiPrep density gradient |
Flotation density |
1.10 g/mL
|
Molecules identified in the study |
Protein |
Methods used in the study |
Mass spectrometry Western blotting |
|
|
3 |
Experiment ID |
275 |
ISEV standards |
✔
EM
|
EV Biophysical techniques |
✔
TSG101|Alix|RAB5A
|
EV Cytosolic markers |
✔
CD9|CD82|CD63|CD81
|
EV Membrane markers |
✔
AIF
|
EV Negative markers |
✔
NTA
|
EV Particle analysis
|
|
Identified molecule |
protein
|
Identification method |
Mass spectrometry
|
PubMed ID |
25844599
|
Organism |
Homo sapiens |
Experiment description |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. |
Authors |
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. |
Journal name |
Oncotarget
|
Publication year |
2015 |
Sample |
Prostate cancer cells |
Sample name |
DU145 - Docetaxel sensitive |
Isolation/purification methods |
Filtration Ultracentrifugation Sucrose density gradient |
Flotation density |
1.12-1.19 g/mL
|
Molecules identified in the study |
Protein |
Methods used in the study |
Mass spectrometry/Flow cytometry/Western blotting |
|
|
Protein-protein interactions for SZT2 |
|
Protein Interactor |
ExoCarta ID |
Identification method |
PubMed |
Species |
No interactions are found.
|
|
Pathways in which SZT2 is involved |
No pathways found
|
|
|